Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema

Current Medical Research and Opinion

Volumn 33, Issue , 2017, Pages 33-43

  Currie, Craig J ^a,b   Holden, Sarah E ^a   Owens, David R ^c  

^a Pharmatelligence   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

central foveal thickness; central subfield thickness; diabetic macular edema; Fluocinolone acetonide; retrospective

Indexed keywords

FLUOCINOLONE ACETONIDE; STEROID; GLUCOCORTICOID;

AGED; ARTICLE; CENTRAL FOVEAL THICKNESS; CENTRAL SUBFIELD THICKNESS; COHORT ANALYSIS; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; FEMALE; FLUOCINOLONE ACETONIDE IMPLANT; FOLLOW UP; HUMAN; INTRAVITREAL IMPLANT; LONGITUDINAL STUDY; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY DEVICE; RETINAL THICKNESS; RETROSPECTIVE STUDY; STEROID THERAPY; VISUAL ACUITY; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED;

AGED; COHORT STUDIES; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 85029778492     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1366662     Document Type: Article

References (34)

1. Chan A, Duker JS, Ko TH, et al. Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 2006;124:193-8
2. Alamouti B, Funk J., Retinal thickness decreases with age: an OCT study. Br J Ophthalmol 2003;87:899-901
3. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35
4. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32
5. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
6. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351-9
7. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22
8. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs. deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81
9. The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203
10. Holden SE, Currie CJ, Owens DR., Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin 2017;33(Suppl):5--17
11. Haukoos JS, Newgard CD., Advanced statistics: missing data in clinical research—part 1: an introduction and conceptual Framework. Acad Emerg Med 2007;14:662-8
12. Wolf-Schnurrbusch UEK, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432-7
13. Sandberg MA, Brockhurst RJ, Gaudio AR, et al. The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2005;46:3349-54
14. Danis RP, Sadda S, Jiao J, et al. Relationship between retinal thickness and visual acuity in eyes with retinal vein occlusion treated with dexamethasone implant. Retina 2016;36:1170-6
15. Ristau T, Keane PA, Walsh AC, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmologica 2014;231:37-44
16. Hannouche RZ, De Avila MP., Retinal thickness measurement and evaluation of natural history of the diabetic macular edema through optical coherence tomography. Arq Bras Oftalmol 2009;72:433-8
17. Diabetic Retinopathy Clinical Research Network. The relationship between OCT-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-36
18. Noda Y, Ogawa A, Toyama T, et al. Long-term increase in subfoveal choroidal thickness after surgery for senile cataracts. Am J Ophthalmol 2014;158:455-9
19. Treumer F, Wacker N, Junge O, et al. Foveal structure and thickness of retinal layers long-term after surgical peeling of idiopathic epiretinal membrane. Invest Ophthalmol Vis Sci 2011;52:744-50
20. Yang Y, Bailey C, Holz FG, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye 2015;29:1173-80
21. Takahashi A, Nagaoka T, Sato E, et al. Effect of panretinal photocoagulation on choroidal circulation in the foveal region in patients with severe diabetic retinopathy. Br J Ophthalmol 2008;92:1369-73
22. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801
23. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2. Ophthalmology 2010;117:1078-86
24. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009;116:2175-81
25. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25
26. The Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77
27. Massin P, Bandello F, Garweg J, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study*). A 12-month randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405
28. National Institute for Health and Care Excellence. Ranibizumab for treating diabetic macular oedema. Technology appraisal guidance [TA274]; 2013. Available at: https://www.nice.org.uk/guidance/ta274. [Last accessed February 27, 2013]
29. National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. Technology appraisal guidance [TA346]; 2015. Available at: https://www.nice.org.uk/guidance/ta346. [Last accessed May 8, 2016]
30. National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy; 2013. Available at: www.nice.org.uk/guidance/ta301. [Last accessed October 24, 2014]
31. El-Ghrably I, Steel DHW, Habib M, et al. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol 2017;27:357-62
32. Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol 2016;16:3
33. Figueira J, Henriques J, Amaro M, et al. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res 2017;57:166-72
34. Massin P, Erginay A, Dupas B, et al. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol 2016;10:1257-64